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Abstract
Background: IL-7 is an essential cytokine in T-cell development and homeostasis. It binds to the IL-7R receptor, a complex of
the IL-7Ra (CD127) and common c (CD132) chains. There is significant interest in evaluating the expression of CD127 on
human T-cells as it often decreased in medical conditions leading to lymphopenia. Previous reports showed the usefulness
of CD127 as a prognostic marker in viral infections such as HIV, CMV, EBV and HCV. A soluble CD127 (sCD127) is released in
plasma and may contribute to disease pathogenesis through its control on IL-7 activities. Measuring sCD127 is important to
define its role and may complement existing markers used in lymphopenic disease management. We describe a new
quantitative assay for the measurement of sCD127 in plasma and report sCD127 concentrations in healthy adults.
Methodology/Principal Findings: We developed a quantitative bead-based sCD127 capture assay. Polyclonal CD127-
specific antibodies were chosen for capture and a biotinylated monoclonal anti-CD127 antibody was selected for detection.
The assay can detect native sCD127 and recombinant sCD127 which served as the calibrator. The analytical performance of
the assay was characterized and the concentration and stability of plasma sCD127 in healthy adults was determined. The
assay’s range was 3.2–1000 ng/mL. The concentration of plasma sCD127 was 1646104 ng/mL with over a log variation
between subjects. Individual sCD127 concentrations remained stable when measured serially during a period of up to one
year.
Conclusions/Significance: This is the first report on the quantification of plasma sCD127 in a population of healthy adults.
Soluble CD127 plasma concentrations remained stable over time in a given individual and sCD127 immunoreactivity was
resistant to repeated freeze-thaw cycles. This quantitative sCD127 assay is a valuable tool for defining the potential role of
sCD127 in lymphopenic diseases.
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Introduction
Interleukin-7 (IL-7) is essential for the development and survival
of human T cells [1]. The IL-7R is a heterodimeric receptor
complex composed of the common cytokine receptor cc chain
(CD132) found in several other cytokine receptors (IL-2R, -4R, -
9R, -15R, and -21R) and the IL-7Ra chain (CD127), also a
component of the Thymic Stromal Lymphopoietin (TSLP)
receptor complex [2–5]. CD127 deficiency due to gene mutations
in the CD127 gene results in severe combined immunodeficiency
(SCID) in both mice and humans [6,7]. Modulation of CD127
expression has been observed in a number of diseases [8–10]. We
and others have demonstrated that significantly fewer CD8
+ T
cells express CD127 in HIV-infected individuals and this
correlates with increased plasma viremia and prognostic markers
such as CD4 depletion and markers of immune activation [11–17]
The mechanism(s) for the loss of membrane-associated CD127 is
an active area of investigation. We and others have also shown
that IL-7 downregulates CD127 expression on CD8
+ T-cells and
CD4
+ T-cells [16,18,19]. In addition to the membrane bound
receptor, a soluble form of the CD127 (sCD127) can be generated
by alternative splicing of mRNA transcripts encoding CD127.
This results in a truncated polypeptide composed of the
extracellular domain and a short 27 amino acid C-terminus
encoded by the altered reading frame. [20,21].
The expression of the alternatively spliced CD127 transcript
was reported in healthy individuals [20] and increased expression
has been described in acute lymphoblastic leukaemia (ALL) [22].
A mutation in the transmembrane domain of CD127 has been
associated with the production of mRNA transcripts encoding
sCD127 in multiple sclerosis patients [23,24]. Soluble CD127 was
initially detected in the supernatant of WI-26VA4 cells, a SV-40
transformed human lung epithelial cell line shown to release
sCD127 using an IL-7 binding assay [25]. Carini et al. described
an assay used to detect sCD127 in the culture supernatants of
human CD8
+ T-cells, however this involved the labour-intensive
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tography column followed by a CD127-specific ELISA [25]. As
IL-7 and surface CD127 are important prognostic indicators in
HIV infection, sCD127 may play a role in the pathogenesis of
HIV and other diseases as well, as is the case with other soluble
cytokine receptors. We report herein the development of a
quantitative capture immunoassay for the measurement of the
sCD127 chain and assess its concentration and stability in the
plasma of healthy individuals.
Results
Assay characteristics
Since this assay was based on capture antibodies that were
developed to be specific for the extracellular domain of a
recombinant form of CD127, the assay reactivity toward the
native form of sCD127 was first established. The human WI cell
line is well characterized for the shedding of the soluble form of
CD127 and was used as a source of native sCD127. Soluble
CD127 released by WI cells after a 24 hour stimulation with IL-7
was detected by the assay anti-CD127 capture antibody (Fig. 1).
The assay specificity was then assessed using WI shed sCD127 as a
competing ligand to anti-CD127 capture antibody. In this
experiment, anti-CD127 antibody coated beads were incubated
with recombinant sCD127-Fc chimera and an excess of native
sCD127 from WI supernatant. The residual binding of the
recombinant sCD127-Fc chimera was quantified using an Fc-
specific biotinylated antibody. The native sCD127 was able to
inhibit the binding of the recombinant sCD127-Fc chimera in a
dose dependent manner and competed out 60% of the
recombinant receptor when undiluted WI cell culture supernatant
(containing 309 ng/mL of native sCD127) was used (Fig. 1 insert).
The sCD127 capture assay was calibrated with purified
recombinant CD127-Fc chimera from 0.1 to 1000 ng/mL
(Fig. 2). Curves generated from 12 separate assays from 2 different
calibrator’s batches and spread over a 9 month-period showed a
mean variation in fluorescence signal of 17% (range 10.6–22.1%)
over the entire calibrator curve (Fig. 2, insert). Inter-assay
precision was established by replicated measures of two samples
of known concentration in 7 assays and showed a mean of
322.1636.5 ng/mL (CV of 11.3%, n=14) and
1006.96162.8 ng/mL (CV of 16.2%, n=13). One sample was
tested in replicates of 14 in 3 assays to assess intra-assay precision
and showed a mean concentration of 256616.4 ng/mL with a
variation of 6.3% (range CV 5.2–8.1%). The minimum detectable
dose, determined as the mean of 30 replicates of the zero
calibrator plus 2 SD was 2.6 ng/mL. The lowest measurable
concentration of sCD127 was 3.2 ng/mL (CV=18%).
Assay linearity was assessed using a two-fold serial dilution (1/
10 to 1/40) of 3 plasma samples with assay diluent. The mean
recovery was 109.5%619.2% (sCD127 323 ng/mL),
109.5%620.2% (sCD127 140 ng/mL) and 100.9%66.8%
(sCD127 270 ng/mL).
The potential interference of IL7 with the measurement of
sCD127 was assessed in a series of samples containing a fixed
concentration of sCD127 and increasing amount of recombinant
IL-7. The presence of IL7 did not interfere with the detection of
sCD127 even when IL-7 was present in excess at a molar ratio of
10 to 1 (data not shown).
sCD127 in healthy adults
Volunteers (n=74) from our facility were recruited for the
determination of sCD127 concentration in healthy adults. Soluble
CD127 concentrations ranged from ,32 ng/mL to 462.6 ng/mL
(mean 164.36104.51 ng/mL) (Fig. 3). Four samples among the 74
tested (5.4%) had concentrations of sCD127 below the detection
limit of the assay. The data range observed from this group of
subjects did not obey a predicted Gaussian distribution (Shapiro-
Figure 1. Detection of native sCD127 using the sCD127 capture bead assay. Detection of native sCD127 in the culture supernatant of
unstimulated (Ctrl) and IL-7-stimulated WI-26VA4 cells using the sCD127 capture bead assay. Insert: Specificity of the sCD127 capture bead assay for
native sCD127. Inhibition of recombinant sCD127-Fc chimera binding to sCD127 assay’s capture antibody by native sCD127. In these experiments,
recombinant sCD127-Fc chimera binding to sCD127 capture antibody conjugated to bead was detected using a Fc-specific detection antibody. The
residual binding is expressed as the percent of the fluorescence signal (MFI) in presence over the signal in absence of native sCD127 from
unstimulated (empty circles) or IL-7-stimulated (filled circles) WI-26VA4 cell culture supernatants.
doi:10.1371/journal.pone.0006690.g001
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were analysed for correlation with gender (38% male, 62% female)
and age (male age 42610; female age 45615; range 21–65 years)
from 29 individuals for which data were available and showed no
statistically significant correlation with either parameter.
Individual plasma sCD127 variation over time
The concentrations of sCD127 were measured in repeat donors
(n=15) tested 2–5 times during a 12-month period (total
samples=39). The sCD127 concentrations remained stable over
time with a mean variation of 30.6635.5 ng/mL (range 0–136.8)
(Fig. 4). This variation represented an average of 14.1611.3%
(range 0–42.4%) from the initial sCD127 measurement.
Effect of freeze-thawing on sCD127 detection
A stability study was undertaken to monitor sCD127 immuno-
reactivity robustness to repeat freezing process. Soluble CD127
concentrations were assessed in plasma samples from 5 individuals
(sCD127 concentrations range 100 to 270 ng/mL). The sCD127
concentrations were stable in all samples for up to 4 cycles of freeze-
thaw with a mean variation of 4.6% (range 0.5–13%) (Table 1).
Discussion
There is increasing interest in the quantification of sCD127 in
human plasma mainly motivated by the pivotal role of the IL-7/
IL-7R pathway in an increasing number of diseases. We and
others have measured sCD127, in vitro and in plasma [19,25].
Carini et al. developed an immunosorbent assay combining
CD127 capture and IL-7 detection to quantify sCD127 in culture
supernatants. This assay had limited sensitivity and required a
substantial amount of sample processing. We have previously
reported semi-quantitative evaluation of sCD127 in human
plasma by Western blot, however this does not constitute a
practical approach for large scale studies. We have described here
the development of a sensitive and reproducible bead-based assay
for the quantitative measurement of human sCD127 in plasma
and report the sCD127 concentrations in healthy individuals.
Figure 2. Calibration curve of the sCD127 capture bead assay.
Recombinant sCD127-Fc chimera was serially diluted from 0.1 to
1000 ng/mL in assay diluent (Materials and Methods) and used as the
assay’s calibrator. The recombinant sCD127 was captured on beads
conjugated with sCD127 polyconal antibodies. Bound sCD127 was
detected with a biotinylated monoclonal anti-CD127 and streptavidin-
PE. The curve was resolved using a 5-parameter logistic equation
(MasterPlex QT software). Insert: Standard curve inter-assay variation
from 12 assays done in duplicates. The curve’s range was 3.2–1000 ng/
mL.
doi:10.1371/journal.pone.0006690.g002
Figure 3. Soluble CD127 concentration distribution in healthy
adults and normal Gaussian curve. Plasma concentrations of
sCD127 (n=74) were determined using a sCD127 capture bead assay.
Each bar represents the number of cases for each interval of sCD127
values and the curve represents the predicted normal distribution. The
mean sCD127 was 164.36104.5 ng/mL.
doi:10.1371/journal.pone.0006690.g003
Figure 4. Serial measurements of sCD127 concentrations in
plasma of healthy individuals. The concentration of sCD127 was
measured in the plasma of repeat donors (n=15) tested 2–5 times over
a one-year period. Individual concentrations of sCD127 remained within
14.1611.3% of their original values (range 0–42%).
doi:10.1371/journal.pone.0006690.g004
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showed sufficient sensitivity to measure sCD127 in 95% of
individuals tested. Matrix effects were avoided by a 10-fold
dilution of plasma samples and the reconstitution of the calibrator
in a negative human plasma control. Since the present assay
included only samples from healthy individuals, potential inter-
ference in pathological plasma samples cannot be excluded. The
sCD127 appears to be a robust protein marker as repeated sample
freeze-thaw cycles and prolonged plasma storage (data not shown)
did not affect detection. This suggests that the sCD127 would be a
valuable marker for retrospective studies using archived samples.
The mean concentration of sCD127 in healthy adults was
164.3 ng/mL and appears to remain stable over time in any given
individual however a wide range of concentrations was observed
between individuals (below 32 ng/mL to over 400 ng/mL). This
variation represents more than a log difference in the population
of healthy individuals studied here. A very recent report by Blom-
Potar et al. [26] investigated the levels of sCD127 in human
plasma using an in-house ELISA. Although not representative of a
population, the mean concentration of sCD127 determined from
the 6 healthy subjects in this study’s control group (23.6 ng/mL)
was much lower than the mean sCD127 concentration reported
here. This difference is likely explained by the different
combination of sCD127 clones used in the ELISA as well as to
the very small number of individuals tested.
It is interesting to note that sCD127 concentrations did not
correlate with percentages of CD4+CD127+ or CD8+CD127+ T-
cells in peripheral blood (data not shown). Whether or not the
concentration of sCD127 varies during episodes of common
innocuous infections or in disease states has not been explored
here and remains to be determined.
Despite previous reports of detecting sCD127 in the culture
supernatants of CD8+ T-cells by Western blot [19], this assay has
failed to detect sCD127 in cultures of human CD8
+ T cells.
However, the assay can detect sCD127 in WI-26VA4 cell culture
supernatants. To date, there has only been one report of a semi-
quantitative method for detecting sCD127 in CD8+ T-cell culture
supernatants, in which sCD127 is first purified using an IL-7-
conjugated affinity chromatography column [25]. This is an
ongoing area of investigation as the detection of sCD127 in vitro
would benefit greatly from a quantitative sCD127 assay.
As reported previously, a limited amount of IL-7 is found in
plasma of healthy individuals [17]. In the present study, the mean
plasma concentration of IL-7 in 29 individuals was low (2.2 pg/
mL, range 0.2–10.5 pg/mL) and no correlation was observed with
circulating levels of sCD127 (data not shown). Attempts were
made to detect sCD127-IL-7 complexes in plasma and WI-26VA4
culture supernatant using the present assay sCD127 capture beads
and a non-neutralizing anti-IL-7 detection monoclonal antibody.
Both plasma and WI supernatant tested contained sCD127 and
IL-7 that could be measured using sCD127 and IL-7 specific
assays. However, no sCD127-IL-7 complexes were detected in the
plasma or in WI cell culture supernatants using the sCD127
capture beads and IL-7 detection antibody (data not shown).
Despite a previous report demonstrating the detection of sCD127-
IL-7 complexes using an ELISA [25], our approach failed to
detect such complexes. Capture of the complexes via polyclonal
antibodies to IL-7 or non-neutralizing IL-7 monoclonal antibody
is presently being investigated. Attempt to measure IL-7
interference in the detection of sCD127 was done by the addition
of exogenous recombinant human IL-7 to a constant concentra-
tion of recombinant sCD127. Our assays demonstrated that the
presence of IL-7 did not interfere with the resulting sCD127
concentrations. If proven to be the case for plasma sCD127 and
IL-7, this assay would provide a useful approach for total sCD127
measurements.
These data support the use of this assay to reliably and
accurately quantify human sCD127 in plasma. In addition, the
mechanism by which the receptor is secreted is an active area of
interest. Potential roles for the sCD127 included the modulation of
circulating IL-7, thereby either limiting IL-7-related activities or
acting as a chaperone and extending the cytokine’s half-life. IL-7 is
critical for T-cell development and is an important factor for T-cell
homeostasis and memory development. The presence of increased
concentrations of sCD127 in the periphery could pose a threat for
the delivery of an adequate amount of IL-7 signals to cells known
to express CD127 such as naı ¨ve and memory CD4
+ and CD8
+ T-
cells. The resulting consequences would likely be reduced IL-7
signaling and function such as decreased expression of anti-
apoptotic molecules, less proliferation, halted cell differentiation
and reduced anti-viral/tumour functions. In addition, peripheral
regulatory T-cells (Tregs), which typically do not express, or
express low levels of CD127 [27–29] might be spared from IL-7
deprivation [30]. This could impact on the ratio of effector T-cells
and Tregs and alter the fine balance governing the immune
response [31]. Studies of the levels of circulating sCD127 in
autoimmune disorders have yet to be done to establish the
potential relation of sCD127 to other markers of autoimmunity.
Several soluble cytokine receptors have been shown to be of
prognostic value in a number of diseases and have also been
developed as therapeutic agents in the treatment of a number of
inflammatory diseases [32]. For example, soluble IL-2Ra (sIL-
2Ra), a marker of immune activation in diseases including
reumatoid arthritis, and various cancers, has proved useful in
monitoring disease progression and early detection of recurrent
disease [33]. Serum sIL-2Ra concentrations in patients with
leukemia and autoimmune diseases can reach concentrations up to
100 fold those found in normal individuals [34]. Soluble IL-2Ra
has been associated with leukemia disease progression and poor
prognosis in children with Hodgkin’s disease [35,36]. Alleles of the
IL-2Ra gene region have been linked to susceptibility and risk to
multiple sclerosis and Type 1 diabetes and these allelic variants
independently correlate with plasma sIL-2Ra concentrations [37].
Increase in soluble TNF receptors can inhibit TNF signaling and
has been shown to prevent TNF-mediated tumour lysis [38]. In its
soluble form, the IL-6 receptor subunit gp130 inhibits the pro-
inflammatory activity of IL-6 [39]. Pre-complexed IL-15-sIL-
15Ra increases NK and CD8
+ T-cell proliferation and anti-
tumour activity up to 50 times compared to IL-15 alone [40–42].
A characterization of sCD127 function and relevance in HIV
infection is forthcoming. The expression of CD127 is decreased in
Table 1. Effect of freeze-thawing on sCD127
immunoreactivity.
Samples Freeze-thaw cycles CV
b
14%
1 270.066.4
a 257.3619.7 3.4
2 99.861.9 100.566.1 0.5
3 185.361.3 154.267.2 13.0
4 269.2613.7 265.463.0 1.0
5 246.3611.2 228.963.0 5.2
asCD127 concentration in ng/mL (mean6SD).
bCV calculation: SD/mean 6100.
doi:10.1371/journal.pone.0006690.t001
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chronic viral infections such as HIV and hepatitis-C virus (HCV)
[16,43–45]. It has been shown that CD127 expression is decreased
in response to IL-7 in vitro while the release of sCD127 increases
[19]. The relevance of sCD127 in HIV infection is of particular
interest, as plasma concentrations of IL-7 are increased in infected
individuals [46].
We specifically developed a bead-based assay as this format
allows for multiplex analysis. Future work involving the addition of
other cytokines and/or soluble cytokine receptors would enhance
the coverage of other pathways and hence, would offer a more
systemic approach to the study of the cytokine network and better
disease prognosis.
The development of a quantitative assay specific to human
sCD127 will be a valuable tool in determining whether sCD127
concentrations are altered in diseases in which the expression of
CD127 is modulated and may assist in investigations of receptor
function. Given that IL-7 is being studied in HIV and cancer
treatments [47,48], measuring sCD127 may be important when
assessing the outcomes of these therapies.
Materials and Methods
Blood collection
All research conducted using blood from human subjects was
approved by the Ottawa Hospital Research Ethics Board on the
basis of written informed consent. A total of 101 plasma samples
were obtained from 74 in-house healthy donors. Whole blood was
collected in K2EDTA-containing Vacutainer Tubes (BD Biosci-
ences) and processed within 2 hours from collection time. Repeat
donors (n=15) were bled 2–5 times over a period of one year.
Cell cultures
The WI-26VA4 human fibroblast cell line (WI, ATCC) was
cultured in RPMI culture medium supplemented with 10% FCS
and penicillin/streptomycin until approximately 80% confluent.
Then the cells were further incubated for 24 or 48 hrs with or
without recombinant human IL-7 (BD Biosciences) at 37uC and
5% CO2. Following the centrifugation of cell pellets, culture
supernatants were collected and stored at 280uC.
Soluble CD127 capture assay
The sCD127 bead-based capture assay was developed after
testing capture and detection antibodies from several commercial
sources (BD Biosciences, Beckman Coulter, eBioSciences, BioLe-
gend, R&D Systems, Sigma-Aldrich). Antibodies were selected for
their ability to capture both the native form of human sCD127
and a recombinant sCD127-Fc chimera (R&D Systems) used as
the assay’s calibrator. Goat anti-human CD127 polyclonal
antibodies (R&D Systems) were covalently coupled to carboxyl-
ated-modified fluorescent beads (Luminex, TX) using carbodii-
mide and N-hydroxysuccinimide as described before [49]. The
antibody-coupled beads were stable for at least one year when kept
in the dark at 4uC. The lyophilized human sCD127-Fc chimera
was reconstituted in phosphate buffer saline (PBS, Canadian Life
Technologies Inc., Canada) containing 0.1% BSA (Sigma-Aldrich)
and kept frozen at 280uC. The calibrator was diluted in assay
diluent consisting of PBS containing 0.05% Tween-20 (Sigma-
Aldrich), 1% BSA, 0.05% NaN3 (Sigma-Aldrich), and 0.9 mg/mL
EDTA (Sigma-Aldrich). The calibrator curve was prepared in
assay diluent containing a 10-fold dilution of a human plasma
(negative control) selected for its undetectable levels of sCD127.
Fifty mL of 10 fold diluted plasma samples in assay diluent were
incubated with the anti-CD127-coated beads (3000/well) for 2 hrs
at room temperature. After 3 washes with PBS containing 0.05%
Tween and 0.9 mg/mL EDTA, the plate was incubated with a
biotinylated mouse anti-human CD127 antibody (BD Biosciences)
diluted in the assay diluent for 1 hr at room temperature. The
plate was washed as before and then incubated with streptavidin-
PE (Molecular Probes) for 10 minutes at room temperature. After
3 washes the samples were analysed on a Luminex-100 System
using the median fluorescence intensity (MFI) of 100 events as the
read-out. The bead analysis was done using the MiraiBio software
(MasterPlex CT, version 1) and the standard curves were
generated using a 5-parameter logistic curve fitting equation
(MasterPlex QT software, version 4, MiraiBio). The assay
background was 162.4614.9 MFI (CV 9.2%, n=30) and the
limit of detection was set at 192.2 MFI (bkg+2 SD).
Competitive binding to anti-CD127 conjugated beads
The culture supernatant of IL-7-stimulated WI cells is known to
contain sCD127 [20] and was used as a source of native sCD127
in these experiments. Two fold dilution of WI cell culture
supernatant (undiluted, 1/2, 1/4, 1/8) from unstimulated and IL-
7-stimulated cultures were incubated with a fixed concentration of
recombinant sCD127-Fc chimera (0.5 ng/mL) and the anti-
sCD127 conjugated beads for 2 hours. Residual recombinant
sCD127-Fc chimera binding to the beads was measured using a
biotinylated anti-human Fc-specific monoclonal antibody (Jackson
ImmunoResarch Laboratories) and was detected with streptavi-
din-PE. The residual binding was expressed as (MFI in presence of
competitor – background)/(MFI in absence of competitor –
background) 6100.
IL-7 interference assay
Soluble CD127 was determined in samples containing a fixed
concentration of recombinant sCD127 (5 ng/mL) in presence of
increasing amount of recombinant IL-7 (BD Biosciences) (range
0.003–15 000 pg/mL; 0–10 IL-7/sCD127 molar ratio). The
sCD127 was measured as described above.
sCD127 freeze-thaw stability
Plasma samples were subjected to 4 cycles of freeze-thaw under
conditions that would mimic handling conditions of plasma used
in repetitive testing. Plasma aliquots of 100 mL were frozen at
280uC, thawed and remained at room temperature for 1 hour.
The cycle was repeated 4 times and the concentration sCD127
was measured.
Statistical analysis
Values are expressed as mean6SD. Correlations were deter-
mined using the Pearson correlation coefficient test and group
comparisons were analysed with the Student’s t-test using the
Sigma-Plot software program (version 11, Systat software).
Distribution and normality analysis were generated using the
Shapiro-Wilk test (SPSS software package, version 12 for
Windows).
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